This site is intended for health professionals only!

Published on 4 April 2013

Share this story:

Generics and biosimilars in Central and Eastern Europe

teaser

Having shown steady recovery from the global economic crisis, the CEE region continues to gain investment from foreign market players, quite a few of which have already successfully established their business in the region.
 
Local market players like Polpharma, Gedeon Richter, Krka, Zentiva and Lek (recently acquired by the Novartis Group), have an impressively strong position within the entire CEE region, becoming a growing subject of interest for the Multinationals and their portfolio ambitions.
With this in mind, CPhI Conferences, in partnership with Polpharma, is proud to present its inaugural conference on Generics and Biosimilars in Central and Eastern Europe which has been designed to assess regulatory hurdles, share best practice and highlight ample market opportunities.
We are delighted to be joined by high-quality industry professionals including IMS Health, MHRA, Janssen Pharmaceuticals, Egis, Polpharma, Selvita and many more. With expert speakers in generic and biosimilar development across the merging markets of CEE, this conference offers the opportunity to network and debate with leaders in this field.
Over the course of two intensive days there will be practical and informative sessions on the current and future market trends, innovation strategies in generic and biosimilar development, identifying the crucial factors in successful partnerships, commercialisation and market access. This is an essential opportunity to gather the information you need to advance your business strategy and establish yourself in this lucrative market.


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine